Protective non-neutralizing SARS-CoV-2 monoclonal antibodies
(2024) In Trends in Immunology 45(8). p.609-624- Abstract
Recent studies show an important role for non-neutralizing anti-spike antibodies, including monoclonal antibodies (mAbs), in robustly protecting against SARS-CoV-2 infection. These mAbs use Fc-mediated functions such as complement activation, phagocytosis, and cellular cytotoxicity. There is an untapped potential for using non-neutralizing mAbs in durable antibody treatments; because of their available conserved epitopes, they may not be as sensitive to virus mutations as neutralizing mAbs. Here, we discuss evidence of non-neutralizing mAb-mediated protection against SARS-CoV-2 infection. We explore how non-neutralizing mAb Fc-mediated functions can be enhanced via novel antibody-engineering techniques. Important questions remain to be... (More)
Recent studies show an important role for non-neutralizing anti-spike antibodies, including monoclonal antibodies (mAbs), in robustly protecting against SARS-CoV-2 infection. These mAbs use Fc-mediated functions such as complement activation, phagocytosis, and cellular cytotoxicity. There is an untapped potential for using non-neutralizing mAbs in durable antibody treatments; because of their available conserved epitopes, they may not be as sensitive to virus mutations as neutralizing mAbs. Here, we discuss evidence of non-neutralizing mAb-mediated protection against SARS-CoV-2 infection. We explore how non-neutralizing mAb Fc-mediated functions can be enhanced via novel antibody-engineering techniques. Important questions remain to be answered regarding the characteristics of protective non-neutralizing mAbs, including the models and assays used for study, the risks of ensuing detrimental inflammation, as well as the durability and mechanisms of protection.
(Less)
- author
- Izadi, Arman
LU
and Nordenfelt, Pontus
LU
- organization
-
- Quantitative immunobiology (research group)
- LU Profile Area: Light and Materials
- LTH Profile Area: Nanoscience and Semiconductor Technology
- NanoLund: Centre for Nanoscience
- LTH Profile Area: Photon Science and Technology
- epIgG (research group)
- SEBRA Sepsis and Bacterial Resistance Alliance (research group)
- publishing date
- 2024-08
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Humans, SARS-CoV-2/immunology, Antibodies, Monoclonal/immunology, COVID-19/immunology, Antibodies, Viral/immunology, Animals, Antibodies, Neutralizing/immunology, Spike Glycoprotein, Coronavirus/immunology, Epitopes/immunology, Immunoglobulin Fc Fragments/immunology
- in
- Trends in Immunology
- volume
- 45
- issue
- 8
- pages
- 609 - 624
- publisher
- Elsevier
- external identifiers
-
- scopus:85199048890
- pmid:39034185
- ISSN
- 1471-4981
- DOI
- 10.1016/j.it.2024.06.003
- language
- English
- LU publication?
- yes
- additional info
- Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
- id
- 561fe88d-29b3-4a5f-8f01-98e6ed5bde30
- date added to LUP
- 2024-08-20 10:13:24
- date last changed
- 2024-09-04 05:44:44
@article{561fe88d-29b3-4a5f-8f01-98e6ed5bde30, abstract = {{<p>Recent studies show an important role for non-neutralizing anti-spike antibodies, including monoclonal antibodies (mAbs), in robustly protecting against SARS-CoV-2 infection. These mAbs use Fc-mediated functions such as complement activation, phagocytosis, and cellular cytotoxicity. There is an untapped potential for using non-neutralizing mAbs in durable antibody treatments; because of their available conserved epitopes, they may not be as sensitive to virus mutations as neutralizing mAbs. Here, we discuss evidence of non-neutralizing mAb-mediated protection against SARS-CoV-2 infection. We explore how non-neutralizing mAb Fc-mediated functions can be enhanced via novel antibody-engineering techniques. Important questions remain to be answered regarding the characteristics of protective non-neutralizing mAbs, including the models and assays used for study, the risks of ensuing detrimental inflammation, as well as the durability and mechanisms of protection.</p>}}, author = {{Izadi, Arman and Nordenfelt, Pontus}}, issn = {{1471-4981}}, keywords = {{Humans; SARS-CoV-2/immunology; Antibodies, Monoclonal/immunology; COVID-19/immunology; Antibodies, Viral/immunology; Animals; Antibodies, Neutralizing/immunology; Spike Glycoprotein, Coronavirus/immunology; Epitopes/immunology; Immunoglobulin Fc Fragments/immunology}}, language = {{eng}}, number = {{8}}, pages = {{609--624}}, publisher = {{Elsevier}}, series = {{Trends in Immunology}}, title = {{Protective non-neutralizing SARS-CoV-2 monoclonal antibodies}}, url = {{http://dx.doi.org/10.1016/j.it.2024.06.003}}, doi = {{10.1016/j.it.2024.06.003}}, volume = {{45}}, year = {{2024}}, }